{"filing":{"accession_number":"0001420720-26-000019","cik":"0001420720","ticker":"IBIO","company_name":"iBio, Inc.","form":"8-K","filing_date":"2026-08-28","report_date":"2026-08-28","primary_document":"ibio-20260828x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072026000019/ibio-20260828x8k.htm"},"events":[{"id":30208,"run_id":27693,"accession_number":"0001420720-26-000019","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"iBio disclosed its fiscal year 2026 financial results (ended June 30, 2026) via press release on August 28, 2026, including consolidated statements of operations and balance sheets. The filing reports a net loss of $33.0 million (vs. $18.4 million prior year), R\u0026D expenses of $19.6 million (up from $8.3 million), and a $5.0 million impairment of indefinite-lived intangible assets. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and cash runway.","company_name":"iBio, Inc.","ticker":"IBIO","filing_date":"2026-08-28","form":"8-K","submitted_at":null,"items":[{"id":32743,"accession_number":"0001420720-26-000019","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"iBio disclosed its fiscal year 2026 financial results (ended June 30, 2026) via press release on August 28, 2026, including consolidated statements of operations and balance sheets. The filing reports a net loss of $33.0 million (vs. $18.4 million prior year), R\u0026D expenses of $19.6 million (up from $8.3 million), and a $5.0 million impairment of indefinite-lived intangible assets. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T12:31:49.798871+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32743,"accession_number":"0001420720-26-000019","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"iBio disclosed its fiscal year 2026 financial results (ended June 30, 2026) via press release on August 28, 2026, including consolidated statements of operations and balance sheets. The filing reports a net loss of $33.0 million (vs. $18.4 million prior year), R\u0026D expenses of $19.6 million (up from $8.3 million), and a $5.0 million impairment of indefinite-lived intangible assets. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T12:31:49.798871+00:00","company_name":"iBio, Inc.","ticker":"IBIO","filing_date":"2026-08-28"}]}